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REVIEW

Understanding the Warburg effect and the
prognostic value of stromal caveolin-1 as a marker
of a lethal tumor microenvironment
Federica Sotgia*1,2,3, Ubaldo E Martinez-Outschoorn1,2,4, Stephanos Pavlides1,2, Anthony Howell3, Richard G Pestell1,2,4
and Michael P Lisanti*1,2,3,4

Abstract
Cancer cells show a broad spectrum of bioenergetic states, with some cells using aerobic glycolysis while others rely
on oxidative phosphorylation as their main source of energy. In addition, there is mounting evidence that metabolic
coupling occurs in aggressive tumors, between epithelial cancer cells and the stromal compartment, and between
well-oxygenated and hypoxic compartments. We recently showed that oxidative stress in the tumor stroma, due to
aerobic glycolysis and mitochondrial dysfunction, is important for cancer cell mutagenesis and tumor progression.
More specifically, increased autophagy/mitophagy in the tumor stroma drives a form of parasitic epithelial-stromal
metabolic coupling. These findings explain why it is effective to treat tumors with either inducers or inhibitors of
autophagy, as both would disrupt this energetic coupling. We also discuss evidence that glutamine addiction in
cancer cells produces ammonia via oxidative mitochondrial metabolism. Ammonia production in cancer cells, in turn,
could then help maintain autophagy in the tumor stromal compartment. In this vicious cycle, the initial glutamine
provided to cancer cells would be produced by autophagy in the tumor stroma. Thus, we believe that parasitic
epithelial-stromal metabolic coupling has important implications for cancer diagnosis and therapy, for example, in
designing novel metabolic imaging techniques and establishing new targeted therapies. In direct support of this
notion, we identified a loss of stromal caveolin-1 as a marker of oxidative stress, hypoxia, and autophagy in the tumor
microenvironment, explaining its powerful predictive value. Loss of stromal caveolin-1 in breast cancers is associated
with early tumor recurrence, metastasis, and drug resistance, leading to poor clinical outcome.

The conventional ‘Warburg effect’ versus oxidative
mitochondrial metabolism
The Warburg eﬀect, also known as aerobic glycolysis, is
deﬁned as the propensity of cancer cells to take up high
levels of glucose and to secrete lactate in the presence of
oxygen. Warburg’s original work indicated that while
glucose uptake and lactate production are greatly
elevated, a cancer cell’s rate of mitochondrial respiration
is similar to that of normal cells [1,2]. He, however,
described it as a ‘respiratory impairment’ due to the fact
that, in cancer cells, mitochondrial respiration is smaller,
relative to their glycolytic power, but not smaller relative
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to normal cells. He recognized that oxygen consumption
is not diminished in tumor cells, but that respiration is
disturbed because glycolysis persists in the presence of
oxygen [1,2]. Unfortunately, the perception of his original
ﬁndings was simpliﬁed over the years, and most subsequent papers validated that cancer cells undergo aerobic
glycolysis and produce lactate, but did not measure
mitochondrial respiration, and just presumed decreased
tricarboxylic acid (TCA) cycle activity and reduced
oxidative phosphorylation [1,2]. It is indeed well documented that, as a consequence of intra-tumoral hypoxia,
the hypoxia-inducible factor (HIF)1α pathway is activated
in many tumors cells, resulting in the direct up-regulation
of lactate dehydrogenase (LDH) and increased glucose
consumption. For updated reviews on the Warburg
eﬀect, the reader is encouraged to refer to the following
papers [3,4].
However, new ﬁndings compel us to reconsider the
current model of cancer cell metabolism. First, not all
tumors are associated with increased aerobic glycolysis,
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and in fact it is now clear that cancer cells utilize both
glycolysis and oxidative phosphorylation to satisfy their
metabolic needs. Experimental assessments of ATP production in cancer cells have demonstrated that oxidative
pathways play a signiﬁcant role in energy generation, and
may be responsible for about 50 to 80% of the ATP
generated [5-8]. Also, it should be considered that most
studies were performed using isolated cancer cells, which
may behave very diﬀerently from cancer cells in vivo, surrounded by their natural microenvironment [9] (see also
Koukourakis and colleagues [10] for another viewpoint).
Second, several studies now clearly indicate that mitochondrial activity and oxidative phosphorylation support
tumor growth. Loss-of-function mutations in the TCA
cycle gene IDH1 (isocitrate dehydrogenase 1) are found
in about 70% of gliomas, but, interestingly, correlate with
a better prognosis and improved survival, suggesting that
severely decreased activity in one of the TCA cycle
enzymes does not favor tumor aggressiveness [11]. The
mitochondrial protein p32 was shown to maintain high
levels of oxidative phosphorylation in human cancer cells
and to sustain tumorigenicity in vivo [12]. In addition,
STAT3 is known to enhance tumor growth and to predict
poor prognosis in human cancers [13]. Interestingly, a
pool of STAT3 localizes to the mitochondria, to sustain
high levels of mitochondrial respiration [14] and to
augment transformation by oncogenic Ras [15,16]. Similarly, the mitochondrial transcription factor A (TFAM),
which is required for mitochondrial DNA replication and
oxidative phosphorylation, is also required for K-Rasinduced lung tumorigenesis [17]. Finally, when constrained to use glycolysis by depletion of mitochondrial
DNA, melanoma B16 cells (B16ρ0) and breast cancer
T47D cells (T47Dρ0), show severe impairment of tumorigenicity in vivo [18,19].
There is also evidence that pro-oncogenic molecules
regulate mitochondrial function. Cyclin D1 inhibits mitochondrial function in breast cancer cells [20]. Overexpression of cyclin D1 is observed in about 50% of
invasive breast cancers and is associated with a good
clinical outcome [21], indicating that inhibition of mitochondrial activity correlates with favorable prognosis.
Importantly, it was shown that the oncogene c-Myc
stimulates mitochondrial biogenesis, and enhances glutamine metabolism by regulating the expression of mitochondrial glutaminase, the ﬁrst enzyme in the glutamine
utilization pathway [22]. Glutamine is an essential
metabolic fuel that is converted to alpha-ketoglutarate
and serves as a substrate for the TCA cycle or for
glutathione synthesis, to promote energy production and
cellular biosynthesis, and to protect against oxidative
stress [23]. Interestingly, pharmacological targeting of
mitochondrial glutaminase inhibits cancer cell transforming activity, suggesting that glutamine metabolism
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and its role in fueling and replenishing the TCA cycle are
required for neoplastic transformation [24] (for a recent
review on glutamine cancer metabolism, see [2]).

The reverse Warburg effect
It is increasingly apparent that the tumor microenvironment regulates neoplastic growth and progression.
Activation of the stroma is a critical step required for
tumor formation. Among the stromal players, cancer
associated ﬁbroblasts (CAFs) have recently taken center
stage [25]. CAFs are activated, contractile ﬁbroblasts that
display features of myo-ﬁbroblasts, express musclespeciﬁc actin, and show an increased ability to secrete
and remodel the extracellular matrix [26,27]. They are
not just neutral spectators, but actively support malignant transformation [28] and metastasis [29], as compared to normal resting ﬁbroblasts. For example, in a
humanized mouse model of breast cancer, oncogenically
driven human organoids develop tumors only if coinjected with immortalized ﬁbroblasts and not with
normal primary ﬁbroblasts, suggesting that stromal
activation is required for breast cancer formation [30].
Importantly, the tumor stroma dictates clinical outcome and constitutes a source of potential biomarkers
[31]. Expression proﬁling has identiﬁed a cancer-associated stromal signature that predicts good and poor
clinical prognosis in breast cancer patients, independently of other factors [32-34].
We and others have recently shown that a loss of
caveolin-1 (Cav-1) in the stromal compartment is a novel
biomarker for predicting poor clinical outcome in all of the
most common subtypes of human breast cancer, including
the more lethal triple negative subtype [35,36]. A loss of
stromal Cav-1 predicts early tumor recurrence, lymphnode metastasis, tamoxifen-resistance, and poor survival.
Overall, breast cancer patients with a loss of stromal Cav-1
show a 20% 5-year survival rate, compared to the 80%
5-year survival of patients with high stromal Cav-1
expression. In triple negative patients, the 5-year survival
rate is 75.5% for high stromal Cav-1 versus 9.4% for absent
stromal Cav-1 [37]. A loss of stromal Cav-1 also predicts
progression to invasive disease in ductal carcinoma in situ
patients, suggesting that a loss of Cav-1 regulates tumor
progression [35]. Similarly, a loss of stromal Cav-1 is
associated with advanced disease and metastasis, as well as
a high Gleason score, in prostate cancer patients [38].
In order to mechanistically dissect how a loss of
stromal Cav-1 induces a lethal microenvironment, we
have employed Cav-1(-/-) null mice as a model system.
Complementary studies were also performed with a coculture model of normal human ﬁbroblasts and MCF7
breast cancer cells.
Unbiased proteomic and transcriptional analysis has
shown that Cav-1(-/-) null bone-marrow-derived stromal

Sotgia et al. Breast Cancer Research 2011, 13:213
http://breast-cancer-research.com/content/13/4/213

cells display the up-regulation of both myo-ﬁbroblast
markers and glycolytic enzymes, clearly indicating that a
loss of Cav-1 promotes myo-ﬁbroblast conversion and
induces aerobic glycolysis in stromal cells [39]. Thus,
stromal cells lacking Cav-1 undergo aerobic glycolysis
and secrete energy-rich metabolites (such as lactate and
pyruvate) that directly feed cancer cells and fuel mitochondrial respiration of adjacent cancer cells. We have
termed this novel hypothesis the ‘reverse Warburg eﬀect’.
This novel idea has now also been independently
conﬁrmed by Pol and colleagues [40], who demonstrated
that genetic ablation of Cav-1 in murine ﬁbroblasts is
indeed suﬃcient to functionally induce the onset of
aerobic glycolysis via mitochondrial dysfunction [40].
Interestingly, immunohistochemistry on human breast
cancers lacking stromal Cav-1 has demonstrated the
over-expression of key glycolytic enzymes, such as PKM2
and LDH, in the ﬁbroblastic tumor stroma [39].
In further support of this hypothesis, co-culture with
cancer cells promotes Cav-1 down-regulation in adjacent
ﬁbroblasts. Importantly, when cultured under homotypic
conditions, MCF7 cancer cells have a very low mitochondrial mass (the conventional Warburg eﬀect). However,
co-culture with ﬁbroblasts, which more closely mirrors
the microenvironment of a naturally occurring tumor,
promotes a very signiﬁcant increase in mitochondrial
mass in MCF7 cancer cells, suggesting that the Warburg
eﬀect might be an in vitro artifact [41]. Importantly,
lactate administration to homotypic MCF7 cancer cell
cultures signiﬁcantly increases mitochondrial mass,
suggesting that lactate administration phenocopies the
presence of reactive ﬁbroblasts [41], by promoting
mitochondrial biogenesis. These new data indicate that
cancer cells and CAFs develop a ‘symbiotic’ or ‘parasitic’
relationship, with the vectorial and unilateral transfer of
energy from glycolytic stromal cells to oxidative cancer
cells (Figures 1 and 2).
Clinically, high glucose uptake has been exploited to
monitor tumor growth using position emission tomography (PET) scanning via radiolabeled 2-deoxy-glucose.
However, we should acknowledge that PET avidity does
not necessarily correlate with high aerobic glycolysis. For
example, PET is not useful in clear cell renal carcinomas
[42,43], which are the tumor ‘prototype’ in which the
Warburg eﬀect should sustain tumor formation. About
half of clear cell renal carcinomas are due to mutations in
the Von Hippel-Lindau (VHL) gene [44,45], leading to
HIF1α constitutive activation and forced induction of
aerobic glycolysis [46-48]. Conversely, little attention is
paid to understanding which cell-type or compartments
within a tumor are most PET avid. In fact, the clinical use
of PET is well established in Hodgkin’s lymphomas [49],
which are composed of less than 10% tumor cells, the rest
being stromal and inﬂammatory cells [50]. Yet, Hodgkin’s

Page 3 of 13

Stromal
Fibroblasts
(CAFs)

Oxidative
Stress

A+

Cancer
Cells

A- or AR

1. Recycled Nutrients
2. Random Mutagenesis
3. Protection Against Apoptosis
Figure 1. The autophagic tumor stroma model of cancer
metabolism. Cancer cells induce oxidative stress in adjacent
cancer-associated fibroblasts (CAFs). This activates reactive oxygen
species (ROS) production and autophagy. ROS production in CAFs,
via the bystander effect, serves to induce random mutagenesis in
epithelial cancer cells, leading to double-strand DNA breaks and
aneuploidy. Cancer cells mount an anti-oxidant defense and upregulate molecules that protect them against ROS and autophagy,
preventing them from undergoing apoptosis. So, stromal fibroblasts
conveniently feed and mutagenize cancer cells, while protecting
them against death. See the text for more details. A+, autophagy
positive; A-, autophagy negative; AR, autophagy resistant.

lymphomas are very PET avid tumors, suggesting that
2-deoxy-glucose uptake may be associated with the
tumor stroma. That the ﬁbrotic component may be
glucose avid is further supported by the notion that PET
is clinically used to assess the therapeutic response in
gastrointestinal stromal tumors (GIST), which are a
subset of tumors of mesenchymal origin. Finally, pilot
clinical studies have shown that PET is useful for
detection of various forms of ﬁbrosis, including pulmonary ﬁbrosis [51].
The reverse Warburg eﬀect can also be described as
‘metabolic coupling’ between supporting glycolytic stromal
cells and oxidative tumor cells. Metabolic cooperativity
between adjacent cell-compartments is observed in
several normal physiological settings. During folliculogenesis and early embryogenesis, oocytes are surrounded
by supporting cumulus granulosa (CG) cells. Oocytes
lack some crucial metabolic functions, such as the ability
to utilize glucose, to produce cholesterol and to transport
certain amino acids. Thus, oocytes control CG cell
metabolism, promoting their glycolysis, cholesterol
synthesis and amino acid uptake [52,53]. Remarkably,
both oocytes and zygotes can reach a two-cell stage only
in the presence of pyruvate and oxaloacetate, but not
using glucose [54,55]. However, upon co-culture with CG
cells, oocytes or zygotes can cleave to a two-cell stage
also in the presence of glucose, clearly indicating that CG
cells metabolize glucose and supply the oocyte with the
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Figure 2. The reverse Warburg effect. (a) Via oxidative stress, cancer cells activate two major transcription factors in adjacent stromal fibroblasts
(hypoxia-inducible factor (HIF)1α and NFκB). This leads to the onset of both autophagy and mitophagy, as well as aerobic glycolysis, which then
produces recycled nutrients (such as lactate, ketones, and glutamine). These high-energy chemical building blocks can then be transferred and
used as fuel in the tricarboxylic acid cycle (TCA) in adjacent cancer cells. The outcome is high ATP production in cancer cells, and protection
against cell death. ROS, reactive oxygen species. (b) Homotypic cultures (upper panels) of MCF7 cells (right) and hTERT-fibroblasts (left) were
immunostained with a mitochondrial membrane antibody (red). Note that mitochondrial mass is lower in mono-cultures of MCF7 cells compared
to fibroblasts. However, co-culture of MCF7 cells with fibroblasts (lower panel) induces a dramatic increase in mitochondrial mass in the ‘central
MCF7 cell colony’, outlined by the dotted white oval. In contrast, mitochondrial mass is decreased in co-cultured fibroblasts. Panel (b) was modified
and reproduced with permission from [41,78].

glycolytic product pyruvate to permit maturation [54]. In
this regard, transcriptional proﬁling of CG cells and
oocytes has revealed that key enzymes of the glycolytic
pathway (aldolase A, enolase 1, LDHA, and PKM2) are
very highly expressed in CG cells, but are undetectable in
oocytes [56]. These results indicate that granulosa cells
support the development and maturation of oocytes and
early embryos by providing them with essential nutrients,
such as oxidative phosphorylation substrates (pyruvate
and lactate [57]), amino acids [58], and cholesterol [59].
Metabolic coupling is also normally observed in the
brain between astrocytes and neurons, and this is known
as ‘neuron-glia metabolic coupling’ [60,61]. In this
regard, glycolytic astrocytes generate high levels of
lactate to support mitochondrial oxidative phosphorylation in adjacent neurons. Consistent with this idea,
LDH is preferentially expressed in astrocytes, and the
mitochondrial enzyme pyruvate dehydrogenase is present

selectively within the neurons [62,63]. Also, in skeletal
muscle it is well established that glycolytic fast-twitch
muscle ﬁbers produce lactate, which is then secreted via
monocarboxylate transporter (MCT) 4. Lactate is then
taken up by the slow-twitch ﬁbers expressing MCT1 and
utilized as a substrate for oxidative phosphorylation
[64,65]. This form of metabolic coupling is known as the
‘skeletal muscle lactate shuttle’ [66].
As such, it is perhaps not surprising that tumors may
have also developed a form of metabolic coupling,
speciﬁcally involving tumor-stromal interactions. In
further support of the existence of a ‘lactate shuttle’ in
human tumors, we have now shown that CAFs express
MCT4 (for lactate extrusion), while breast cancer cells
express MCT1 (for lactate uptake) (Figure 3) [67].
Interestingly, MCT4 expression in CAFs is induced by
oxidative stress, and MCT4 is a known HIF1α target gene
(see Discussion below) [67].

Sotgia et al. Breast Cancer Research 2011, 13:213
http://breast-cancer-research.com/content/13/4/213

(a)

Page 5 of 13

(b)

MCT4

MCT1

(c)

ENERGY TRANSFER MECHANISM

Cancer Cells

CAFs
MCT4

MCT1
Lactate
Ketones

Figure 3. Evidence supporting a ‘lactate shuttle’ in human tumors: compartmentalized distribution of monocarboxylate transporter
(MCT)1/4. (a) MCT4 is expressed in the fibroblastic stromal compartment of human breast cancers. Note that MCT4 staining is absent from the
tumor epithelial cells, but is present in the surrounding stroma. MCT4 staining outlines the cancer-associated fibroblasts that surround nests of
epithelial cancer cells. (b) MCT1 is expressed in the epithelial compartment of human breast cancers. Note that MCT1 staining is present in the
tumor epithelial cells, but is absent in the surrounding stroma. (c) The lactate shuttle: an energy transfer mechanism in normal tissue and human
cancers. MCT4 functions primarily as a transporter that extrudes lactate from cells that are undergoing aerobic glycolysis and lack functional
mitochondria. After lactate is extruded by MCT4 in cancer-associated fibroblasts (CAFs), lactate is then taken up by MCT1 in adjacent cancer cells.
Similarly, ketones are transported by the same MCTs that handle lactate. Our studies suggest that metabolic coupling occurs between CAFs and
adjacent tumor cells. Modified and reproduced with permission from [67].

Oxidative stress: random mutagenesis and
protection against cell death
Recent studies have dissected the mechanism(s) by which
a loss of stromal Cav-1 leads to an aggressive breast
cancer phenotype, and have shown that oxidative stress
plays a central role. The role of oxidative stress in sustaining tumor growth is underscored by the observation
that reactive oxygen species (ROS)-mediated myo-ﬁbroblast conversion is suﬃcient to reduce tumor-free survival, and increases metastatic potential in a mammary
tumor mouse model [68].

Gene expression proﬁling of Cav-1(-/-) null bonemarrow-derived stromal cells has shown the upregulation of gene transcripts associated with ROS production, and over-expression of the transcriptional targets
of HIF1α and NFκB, suggesting that a loss of stromal
Cav-1 induces oxidative stress, mimics hypoxia, and
stimulates inﬂammation [41].
Co-cultures of normal human ﬁbroblasts and MCF7
cells indicate that cancer cells use oxidative stress as a
weapon to trigger the conversion of adjacent ﬁbroblasts
into myo-ﬁbroblasts [69]. Cancer cell-induced oxidative
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stress potently perturbs the behavior of adjacent ﬁbroblasts, induces the lysosomal-mediated degradation of
Cav-1, and promotes mitochondrial dysfunction, resulting in increased aerobic glycolysis [41]. In turn, these
glycolytic ﬁbroblasts support tumor cell mitochondrial
respiration and growth by actively transferring highenergy nutrients (such as lactate and pyruvate) to cancer
cells.
In support of the ‘reverse Warburg eﬀect’, comparison
of the tumor-promoting properties of two ﬁbroblast lines
(named CL3 and CL4) with either mitochondrial or
glycolytic metabolism has revealed that aerobic glycolysis
in CAFs greatly promotes tumor formation. CL3 ﬁbroblasts show oxidative metabolism and increased mitochondrial mass, whereas CL4 ﬁbroblasts display a shift
towards aerobic glycolysis and increased lactate production [70]. Interestingly, in a xenograft model, CL4 ﬁbroblasts enhance the growth of mammary tumors by
approximately eight-fold compared to CL3 cells, without
a detectable increase in angiogenesis. Consistent with this
growth-promoting eﬀect, CL4 ﬁbroblasts also increase the
mitochondrial mass of co-cultured breast cancer cells [71].
An oxidative-stress-rich micro-environment generates
DNA damage in both cancer and stromal cells (Figure 1).
We have shown that MCF7 cancer cells induce oxidative
stress and promote DNA double-strand breaks in
associated stromal cells, which are blocked by antioxidant treatments [41]. Similarly, after three-dimensional co-culture with prostate cancer cells, bone-derived
stromal cells undergo stable cytogenetic modiﬁcations by
a ROS-mediated mechanism [72].
Conversely, in an MCF7-ﬁbroblast co-culture model,
MCF7 cancer cells undergo aneuploidy and random
mutagenesis [41], suggesting that CAFs facilitate the
dynamic search for a more aggressive ‘mutator phenotype’ in cancer cells (Figure 1). Functionally, ﬁbroblasts
provide cancer cells with a six-fold protection against cell
death [41] (Figure 2), via the up-regulation of the antiapoptotic protein TIGAR [41]. Cav-1 knockdown ﬁbroblasts provide even greater protection for cancer cells
against apoptosis, clearly indicating that a loss of stromal
Cav-1 in humans may greatly facilitate tumor growth by
suppression of cancer cell death [41].
Thus, data supporting the ‘reverse Warburg eﬀect’
indicate that cancer cells and ﬁbroblasts are metabolically
coupled and mutagenically co-evolving [41,73]. Cancer
cells use oxidative stress to corrupt adjacent ﬁbroblasts
and to induce their metabolic re-programming [73]. In
this way, ﬁbroblasts secrete energy rich metabolites that
facilitate cancer cell survival. In addition, ﬁbroblasts
promote mutagenesis of cancer cells, leading to a more
aggressive ‘aneuploid’ phenotype [41,73]. Aneuploidy in
cancer cells is known to be associated with poor clinical
outcome.
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Hypoxia, autophagy, and mitophagy in the tumor
stroma
Metabolomic proﬁling reveals that Cav-1(-/-) null mammary fat pads display a highly catabolic metabolism, with
the increased release of several metabolites, such as
amino acids, ribose and nucleotides, and a shift towards
gluconeogenesis, as well as mitochondrial dysfunction
[74]. These changes are consistent with increased autophagy, mitophagy and aerobic glycolysis, all processes
that are induced by oxidative stress [74]. Autophagy or
‘self-eating’ is the process by which cells degrade their
own cellular components to survive during starvation or
to eliminate damaged organelles after oxidative stress.
Mitophagy, or mitochondrial-autophagy, is particularly
important to remove damaged ROS-generating
mitochondria.
An autophagy/mitophagy program is also triggered by
hypoxia [75,76]. Hypoxia is a common feature of solid
tumors, and promotes cancer progression, invasion and
metastasis [77]. Interestingly, via induction of autophagy,
hypoxia is suﬃcient to induce a dramatic loss of Cav-1 in
ﬁbroblasts. The hypoxia-induced loss of Cav-1 can be
inhibited by the autophagy inhibitor chloroquine, or by
pharmacological inhibition of HIF1α [69,78]. Conversely,
small interfering RNA-mediated Cav-1 knock-down is
suﬃcient to induce pseudo-hypoxia, with HIF1α and
NFκB activation, and to promote autophagy/mitophagy,
as well as a loss of mitochondrial membrane potential in
stromal cells [78]. These results indicate that a loss of
stromal Cav-1 is a marker of hypoxia and oxidative stress.
In a co-culture model, autophagy in cancer-associated
ﬁbroblasts was shown to promote tumor cell survival via
the induction of the pro-autophagic HIF1α and NFκB
pathways in the tumor stromal microenvironment [78].
Finally, the mitophagy marker Bnip3L is selectively upregulated in the stroma of human breast cancers lacking
Cav-1, but is notably absent from the adjacent breast
cancer epithelial cells [78].
Another study has shown that cell-speciﬁc induction of
autophagy by HIF1α activation in ﬁbroblasts or MDAMB-231 cells diﬀerentially aﬀects tumor growth. In a
xenograft model, HIF1α activation in ﬁbroblasts greatly
enhances the tumorigenicity of co-injected MDA-MB-231
cells, whereas HIF1α activation in MDA-MB-231 cancer
cells suppresses tumor growth [79]. Importantly, in this
experimental setting, the levels of tumor angiogenesis
were unchanged. As HIF1α triggers autophagy in both
ﬁbroblasts and cancer cells, these data demonstrate that
the role of autophagy in driving tumor formation is celltype speciﬁc, and that stromal autophagy, and not cancer
cell autophagy, favors tumor growth.
Several studies have demonstrated that the overexpression of autophagic markers, such as ATG16L and
cathepsin K and D, in the stroma and not in tumor cells
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predicts poor prognosis [80-82]. Similarly, loss of autophagic markers, such as Beclin 1, in tumor cells correlates
with poor clinical outcome, suggesting that activation of
an autophagic program in tumor cells reduces tumor
aggressiveness [83].
Metabolome proﬁling of several types of human cancer
tissues versus corresponding normal tissues have consistently shown that cancer tissues are highly catabolic, with
the signiﬁcant accumulation of many amino acids and
TCA cycle metabolites [84,85]. The levels of reduced
glutathione were decreased in primary and metastatic
prostate cancers compared to benign adjacent prostate
tissue, suggesting that aggressive disease is associated
with increased oxidative stress [86]. Also, these data
show that the tumor microenvironment has increased
oxidative-stress-induced autophagy and increased
catabolism.
Taken together, all these ﬁndings suggest an integrated
model whereby a loss of stromal Cav-1 induces autophagy/
mitophagy in the tumor stroma, via oxidative stress. This
creates a catabolic micro-environment with the local
accumulation of chemical building blocks and recycled
nutrients (such as amino acids and nucleotides), directly
feeding cancer cells to sustain their survival and growth.
We have termed this novel idea the ‘autophagic tumor
stroma model of cancer’ [74]. This new paradigm may
explain the ‘autophagy paradox’, which is based on the
fact that both the systemic inhibition and systemic
stimulation of autophagy prevent tumor formation [87].
We propose that vectorial energy transfer from the tumor
stroma to cancer cells directly sustains tumor growth,
and that interruption of such metabolic coupling will
block tumor growth. Autophagy inhibitors (such as
chloroquine) functionally block the catabolic transfer of
metabolites from the stroma to the tumor, inducing
cancer cell starvation and death [88]. Conversely,
autophagy inducers (such as rapamycin) promote
autophagy in tumor cells and induce cell death [89]. Thus,
both inhibitors and inducers of autophagy will have a
similar eﬀect by severing the metabolic coupling of the
stroma and tumor cells, resulting in tumor growth
inhibition (cutting ‘oﬀ ’ the fuel supply).
This model may also explain why enthusiasm for antiangiogenic therapy has been dampened. In most cases,
the clinical beneﬁts are short term, and more importantly,
new data suggest an unexpected link between anti-angiogenic treatments and metastasis. In pre-clinical models,
anti-vascular endothelial growth factor (anti-VEGF)
drugs (sunitinib and anti-VEGFR2 blocking antibodies)
were shown to inhibit localized tumor formation, but
potently induced relapse and metastasis [90-92]. Thus, by
inducing hypoxia in the tumor microenvironment, antiangiogenic drugs may create a more favorable metastatic
niche [93]. Hypoxia-induced autophagy may play a role
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by generating a catabolic micro-environment rich in
chemical building blocks that can be directly used by
cancer cells to sustain malignant transformation and
metastatic progression.
Finally, the autophagic tumor stroma model can also
provide an explanation for systemic cachexia, which is
progressive skeletal muscle and adipose tissue wasting,
aﬀecting up to 50% of all cancer patients and resulting in
severe weight loss and shortened survival [94]. Cachexia
is the result of increased energy consumption and higher
metabolic rates [95]. Based on our data, we envision that
cancer leads to a generalized catabolic state via an
autophagic-mechanism that generates building blocks
and starves the rest of the body. While the exact signaling
pathways governing this phenomenon are not yet fully
elucidated, it is clear that oxidative stress-induced autophagy functions as a driver of muscle wasting [96]. For
example, skeletal muscles from tumor-bearing mice
showed impaired Akt activation and a more than 50-fold
induction of Bnip3, a well recognized marker of
autophagy/mitophagy [97]. These ﬁndings also help
explain why patients with metabolic syndrome and
diabetes have an increased risk for the development of
multiple epithelial cancers, due to their constitutive and
systemic activation of the autophagic program, and the
over-production of high-energy nutrients, such as lactate
and ketones [74].
We have recently used laser-capture micro-dissection
of the tumor stroma from human breast cancers to
directly validate that a loss of stromal Cav-1 is transcriptionally associated with oxidative stress, hypoxia,
autophagy, and mitochondrial dysfunction, via gene-set
enrichment analysis (Figure 4) [98]. In addition, we see
that oxidative stress in CAFs induces cytokine production
via NFκB activation, directly linking inﬂammation with
autophagy/catabolism in the tumor stroma [99]. So,
cachexia may start locally as stromal autophagy, and then
spread systemically via cytokine production and inﬂammation, which also drive autophagy [99].

Glutamine utilization, ammonia production, and
autophagy in the tumor stroma
In direct support that cancer cells use mitochondrial
oxidative metabolism, many investigators have shown
that cancer cells are ‘addicted’ to glutamine [24,100].
Glutamine is a non-essential amino acid that is metabolized to glutamate and enters the TCA cycle as alphaketoglutarate, resulting in high ATP generation via oxidative phosphorylation [2,22,101-103].
Recent studies also show that ammonia is a by-product
of glutaminolysis [104-106]. In addition, ammonia can
act as a diﬀusible inducer of autophagy [104-106]. Given
these observations, glutamine addiction in cancer cells
provides another mechanism for driving and/or
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Figure 4. Molecular profiling of a Cav-1 deficient tumor micro-environment in breast cancer patients. (a) The transcriptional profiles
of caveolin-1 (Cav-1)-positive (+) tumor stroma (N = 4) versus Cav-1-negative (-) tumor stroma (N = 7) were compared, via laser-capture
microdissection. We identified 238 gene transcripts that were up-regulated and 232 gene transcripts that were down-regulated in the stroma of
tumors showing a loss of Cav-1 expression. Note that the two patient populations are transcriptionally distinct. (b) The Cav-1-deficient stromal gene
signature is associated with poor survival in estrogen receptor-positive and luminal A breast cancer patients. Note that the Cav-1-deficient stromal
signature is clearly associated with decreased overall survival. (c) Heat maps of the gene transcripts associated with the response to hypoxia,
glycolysis, and autophagy. Note that Cav-1-deficient stroma shows the up-regulation of hypoxia target genes (65 transcripts), glycolysis/pyruvate
metabolism (15 transcripts), and autophagy (22 transcripts). Modified and reproduced with permission from [98].
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maintaining autophagy in the tumor micro-environment
(Figure 5). In support of this idea, we have previously
shown that a loss of Cav-1 in the stroma is suﬃcient to
drive autophagy, resulting in increased glutamine
production in the tumor micro-environment [74].
Thus, this concept deﬁnes a new vicious cycle in which
autophagy in the tumor stroma transfers glutamine to
cancer cells, and the by-product of this metabolism,
ammonia, maintains autophagic glutamine production
(Figure 5). This model ﬁts well with the ‘autophagic tumor
stroma model of cancer metabolism’, in which energyrich recycled nutrients (lactate, ketones, and glutamine)
fuel oxidative mitochondrial metabolism in cancer cells.

Lessons from other paradigms: an infectious
parasitic cancer cell that metastasizes and captures
mitochondrial DNA from host cells
We have recently proposed that cancer cells behave like
‘parasites’, by inducing oxidative stress in normal host
ﬁbroblasts, resulting in the production of recycled
nutrients via autophagy [41,69,78]. This is exactly the
same mechanism by which infectious parasites (such as
malaria) obtain nutrients and are propagated by inducing
oxidative stress and autophagy in host cells [107-109]. In
this regard, malaria is an ‘intracellular’ parasite, while
cancer cells may be thought of as ‘extracellular’ parasites.
This explains why chloroquine is both an eﬀective antimalarial drug and an eﬀective anti-tumor agent, as it
functions as an autophagy inhibitor [110], cutting oﬀ the
‘fuel supply’ in both disease states.
Are there any examples of cancer cells that act as
infectious parasites? Surprisingly, the answer is yes [111].
There are four known types: canine transmissible
venereal tumor (CTVT), which is a sexually transmitted
disease that occurs in feral dogs [112] - it is transmitted
through coitus, licking/biting, or sniﬃng; devil facial
tumor disease, spread among Tasmanian devils via facial
biting [113,114]; contagious reticulum cell sarcoma,
which is transmitted between Syrian hamsters via
mosquito bites [115,116]; and malignant ﬁbrous histiocytoma, which was transmitted from a cancer patient to
his surgeon [117] during an injury that occurred when
the surgeon was operating.
These parasitic cancers are all transmitted by allografting, so the cancer cells literally ‘metastasize’ from
one aﬀected host to another ‘naïve’ host, in an infectious
manner that does not involve a virus.
Experimentally, the most is known about CTVT. This
disease is thought to have originated in ancient wolves or
coyotes, and the tumor cells themselves act as the
infectious agent. As such, these cancer cells are
genetically distinct from their hosts, as determined by
genomic sequence analysis of their nuclear DNA [118].
CTVT represents the oldest known cancer cell line that
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Figure 5. Glutamine utilization in cancer cells and the tumor
stroma. Oxidative mitochondrial metabolism of glutamine in cancer
cells produces ammonia. Ammonia production is sufficient to
induce autophagy. Thus, autophagy in cancer-associated fibroblasts
provides cancer cells with an abundant source of glutamine. In turn,
the ammonia produced maintains the autophagic phenotype of the
adjacent stromal fibroblasts. See text for details. TCA, tricarboxylic
acid.

has been continuously propagated, most likely for more
than 10,000 years [118,119].
Interestingly, it has recently been shown that CTVT
tumor cells survive by periodically ‘capturing’ mitochondrial DNA from their hosts [119,120]. Thus, it has been
suggested that these CVCT tumor cells have survived for
more than 10,000 years by maintaining and renewing
their capacity for oxidative mitochondrial metabolism by
‘stealing’ host cell mitochondrial DNA [119,120]. In
accordance with this idea, CTVT is highly sensitive to
adriamycin/doxorubicin therapy [121], a chemo-therapeutic
agent that also functions as a mitochondrial poison.
Similarly, it has been independently shown that human
cancer cells can ‘steal’ live mitochondria or mitochondrial
DNA [122] from adjacent mesenchymal stem cells in
culture, which then rescues aerobic glycolysis in these
cancer cells [122]. This is known as mitochondrial
transfer [122]. Interestingly, others have shown that
metastatic breast cancer cells show the up-regulation of
numerous mitochondrial proteins [123], speciﬁcally
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injection of lactate in an MDA-MB-231 xenograft model
results in an approximately ten-fold increase in lung
metastasis [125].
Abbreviations
CAF, cancer associated fibroblast; Cav, caveolin; CTVT, canine transmissible
venereal tumor; HIF, hypoxia-inducible factor; LDH, lactate dehydrogenase;
MCT, monocarboxylate transporter; NF, nuclear factor; PET, position emission
tomography; ROS, reactive oxygen species; TCA, tricarboxylic acid.
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(b)

Figure 6. Lactate treatment of estrogen receptor-positive
breast cancer cells drives mitochondrial biogenesis, leading to
poor survival in a subset of luminal A breast cancer patients.
(a) Lactate-treated (10 mM) MCF7 cells show a significant increase
in mitochondrial mass, as visualized by staining with antibodies
against mitochondrial marker proteins. (b) Lactate-treated (10 mM)
MCF7 cells were subjected to transcriptional profiling (exon-array)
to generate a gene signature. Interestingly, this lactate-induced
gene signature predicts poor clinical outcome in estrogen receptorpositive/luminal A breast cancer patients, which represent nearly
60 to 70% of cases, and is the most common type of breast cancer.
Modified and reproduced with permission from [124].

associated with oxidative phosphorylation, as seen by
unbiased proteomic analysis [123].
Thus, increased mitochondrial oxidative metabolism
may be a key driver of tumor cell metastasis. In further
support of this argument, treatment of MCF7 cancer
cells with lactate is indeed suﬃcient to induce
mitochondrial biogenesis in these cells [41,78] (Figure 6).
To determine if these ﬁndings may be clinically relevant,
a lactate-induced gene signature was recently generated
using MCF7 cells [124]. This gene signature shows that
lactate induces ‘stemness’ in cancer cells, and this lactateinduced gene signature predicts poor clinical outcome
(including tumor recurrence and metastasis) in breast
cancer patients [124] (Figure 6). These ﬁndings are
consistent with experiments showing that intraperitoneal
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